Operation Manual
Table Of Contents
- 1. Quick Start
- 2. Introduction
- 3. Getting Started
- 3.1. Installation
- 3.2. Injector Features
- 3.3. Symbols
- 3.3.1. Symbols used in this manual
- 3.3.2. Symbols used on labelling
- 3.3.3. Handswitch and Footswitch
- 3.3.4. Icons and Buttons used on the Injector Touch Screen Graphical Interface
- 3.3.5. Injector Buttons
- 3.3.6. Remote Control Symbols and Buttons
- 3.3.7. Injector Visual Indicators
- 3.3.8. Icons and Buttons used on the RCU Touch Screen Graphical Interface
- 4. Clinical Information
- 5. Operation Description
- 5.1. Turning the System On for the First Time
- 5.2. Syringe, Quick Fill Tube, Fill Spike, and Connector Tubes
- 5.3. Filling a Syringe Using a Quick Fill Tube (QFT) or Fill Spike on the Injector
- 5.4. [Optional] Off-line Filling
- 5.5. Connector Tube Installation
- 5.6. Dismounting a Syringe
- 5.7. Performing an injection
- 5.8. Programming
- 5.9. Options Menu
- 5.10. [RCU models] Operation Description with Remote Control Unit
- 5.10.1. RCU Features–
- 5.10.2. The Injector and the RCU
- 5.10.3. Turning the System On / Off
- 5.10.4. Injector Controller Application
- 5.10.5. Filling State
- 5.10.6. Routine Protocol
- 5.10.7. Arming
- 5.10.8. Check for Air
- 5.10.9. Starting the Injection
- 5.10.10. Injection in Progress
- 5.10.11. Injection Control Buttons
- 5.10.12. Injection Review
- 5.10.13. Protocol Edit
- 5.10.14. Edit Lock
- 5.10.15. Parameter Value Edit
- 5.10.16. Injecting remaining volume
- 5.10.17. Edit Phase Type
- 5.10.18. Open Protocol
- 5.10.19. Protocol Save
- 5.10.20. Common Injecting Alarms / Warnings
- 5.10.21. RCU Manager
- 5.10.22. RCU Setup
- 5.10.23. History Viewer
- 5.10.24. Protocol Manager
- 5.10.25. eGFR (glomerular filtration rate) Calculator
- 5.11. [Optional] DC200 Scanner Interface
- 5.12. [Optional] Protocol Assistance Tool (PAT)
- 6. Cleaning and Maintenance
- 7. Trouble-shooting
- 8. Specifications
- 8.1. Dimensions
- 8.2. Mechanical
- 8.3. Functional
- 8.4. Controls
- 8.5. Environmental
- 8.6. Electrical
- 8.7. Connectors
- 8.8. IEC 60601-1 Classifications
- 8.9. Ground Continuity
- 8.10. RoHS Statement
- 8.11. IEC60601-1-2:2014 (4th Ed) Compliance
- 8.12. Models
- 8.13. Accessories
- 8.14. Manufacturer’s Software License Information
- 8.15. FCC Statement
- 9. Index
90 MEDRAD
®
Salient Operation Manual
Immunity test IEC 60601-1-2 test compliance level Electromagnetic environment guidance
Portable and mobile RF communication equipment should be
used no closer to any part of the Salient contrast injector than the
recommended separation distance calculated from the equation
applicable to the frequency of the transmitter.
Recommended separation distance:
Conducted RF
IEC 61000-4-6
3 Vrms at 1kHz 80% AM
150 kHz to 80 MHz
d = 1.2√P
Radiated RF
IEC 61000-4-3
3 V/m at 1kHz 80% AM
80 MHz to 2.7GHz
Proximity Fields
385 – 5785 MHz, 9 – 27 V/m
d = 1.2√P 80 MHz to 800 MHz
d = 2.3√P 800 MHz to 2.7GHz
where P is the maximum output power rating of the transmitter
in watts (W) according to the transmitter manufacturer and d is
the recommended separation distance in metres (m).
Field strengths from fixed RF transmitters, as determined by an
electromagnetic site survey,
a
should be less than the compliance
level in each frequency range.
b
Interference may occur in the vicinity of equipment marked with
this symbol:
NOTE 1
NOTE 2
At 80 MHz and 800 MHz, the higher frequency range applies.
These guidelines may not apply in all situations. Electromagnetic propagation is affected by absorption and
reflection from structures, objects and people.
a
Field strengths from fixed transmitters, such as base stations for radio (cellular/cordless) telephones and land
mobile radios, amateur radio, AM and FM radio broadcast and TV broadcast cannot be predicted theoretically
with accuracy. To assess the electromagnetic environment due to fixed RF transmitters, an electromagnetic
site survey should be considered. If the measured field strength in the location in which the injector is used
exceeds the applicable RF compliance level above, the injector should be observed to verify normal
operation. If abnormal performance is observed, additional measures may be necessary, such as reorienting or
relocating the injector.
b
Over the frequency range 150 kHz to 80 MHz, field strengths should be less than 3 V/m.